Nova Agritech reported a consolidated PAT of Rs 12.84 crore for FY26, down from Rs 27.42 crore last year. The decline follows a 11% drop in revenue caused by regulatory delays in biostimulant licensing. With licenses now renewed and production capacity significantly increased at its new plants, the company aims to regain growth momentum in the coming fiscal year.
Nova Agritech Reports FY26 Financials Amid Capacity Expansion
Nova Agritech Limited reported a Consolidated PAT of Rs 12.84 crore for FY 2025-26.
Consolidated Total Income for the period stood at Rs 261.76 crore.
Reader Takeaway: License renewals and increased capacity offer recovery potential, though margin pressure remains a key watch point.
What just happened
Nova Agritech released its Annual Report for FY 2025-26, reflecting a period of mixed operational results. While the company successfully commissioned a new formulation plant at its NASPL unit in June 2025, overall financial performance faced headwinds. Total income dropped to Rs 261.76 crore from Rs 296.60 crore the previous year, while profitability saw a sharper contraction due to regulatory challenges.
Why this matters
The financial dip was specifically tied to the implementation of the new biostimulant act. Delays in obtaining necessary state-level license renewals hindered the company's ability to sell its biostimulant portfolio for part of the year. Management confirmed that the critical license was renewed in January 2026, allowing operations to resume fully. Shareholders are now watching to see how effectively the company can utilize its expanded footprint—which increased capacity to 14,592 MT for NATL and 13,269 MT for NASPL—to recover lost revenue.
Governance and Board Updates
The company announced several leadership changes alongside its annual results. Mr. Lakshmi Satish Tata was appointed as CFO in November 2025. Additionally, shareholders will vote on the re-appointment of directors including Mrs. Malathi Siripurapu and Mr. Rajesh Cherukuri during the upcoming AGM on September 26, 2026. Mr. Kiran Kumar Adapa stepped down as an Independent Director in February 2026.
Risks to watch
Investors should monitor the company's ability to stabilize margins as it scales up production at the new facilities. Furthermore, the agricultural sector remains sensitive to regulatory shifts, and continued compliance with evolving biostimulant norms is essential for maintaining consistent revenue streams in FY27.
What to track next
The primary focus for the market will be the quarterly earnings trajectory in FY27 to determine if the post-expansion capacity utilization translates into improved profitability and revenue growth.